128 related articles for article (PubMed ID: 36722026)
21. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
[TBL] [Abstract][Full Text] [Related]
22. Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222.
Perkmann T; Perkmann-Nagele N; Mucher P; Radakovics A; Repl M; Koller T; Jordakieva G; Wagner OF; Binder CJ; Haslacher H
Int J Infect Dis; 2021 Sep; 110():309-313. PubMed ID: 34332084
[TBL] [Abstract][Full Text] [Related]
23. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers.
Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Kim HS
Front Immunol; 2022; 13():859019. PubMed ID: 35720318
[TBL] [Abstract][Full Text] [Related]
24. Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
EJIFCC; 2022 Aug; 33(2):166-174. PubMed ID: 36313914
[TBL] [Abstract][Full Text] [Related]
25. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine.
Ferrari D; Ambrosi A; Di Resta C; Tomaiuolo R; Locatelli M; Banfi G
J Immunol Methods; 2022 Jul; 506():113293. PubMed ID: 35660546
[TBL] [Abstract][Full Text] [Related]
27. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
[TBL] [Abstract][Full Text] [Related]
28. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
29. Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic.
Costanzo GAML; Deiana CM; Sanna G; Perra A; Campagna M; Ledda AG; Coghe F; Palmas V; Cappai R; Manzin A; Chessa L; Del Giacco S; Firinu D
J Clin Immunol; 2023 Dec; 44(1):12. PubMed ID: 38129351
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
De Cagna MR; Colucci V; Di Maggio A; Notaristefano N; Cianciotta F; Danza K; Salvatore F; Santoniccolo A; Lanzillotta SG; Perniola MA; Marangi AL; Morrone LFP; Tampoia M
Clin Exp Nephrol; 2023 May; 27(5):445-453. PubMed ID: 36795176
[TBL] [Abstract][Full Text] [Related]
31. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():839922. PubMed ID: 35309303
[TBL] [Abstract][Full Text] [Related]
32. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
[TBL] [Abstract][Full Text] [Related]
33. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
34. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y
Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457
[TBL] [Abstract][Full Text] [Related]
36. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
38. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
39. The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay.
Salvagno GL; Henry BM; Lippi G
Int J Infect Dis; 2021 Oct; 111():65-67. PubMed ID: 34455083
[TBL] [Abstract][Full Text] [Related]
40. Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection.
Bingula R; Chabrolles H; Bonnet B; Archimbaud C; Brebion A; Cosme J; Ollier A; Dutheil F; Junda M; Mirand A; Regagnon C; Vidal M; Henquell C; Evrard B
Emerg Microbes Infect; 2023 Dec; 12(1):2184176. PubMed ID: 36848040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]